Liang TY, Lu LH, Tang SY, Zheng ZH, Shi K, Liu JQ. Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome. World J Stem Cells 2023; 15(4): 150-164 [PMID: 37180997 DOI: 10.4252/wjsc.v15.i4.150]
Corresponding Author of This Article
Jing-Quan Liu, MD, Doctor, Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), No. 158 Shangtang Road, Gongshu District, Hangzhou 310014, Zhejiang Province, China. liujqaticu@163.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Apr 26, 2023; 15(4): 150-164 Published online Apr 26, 2023. doi: 10.4252/wjsc.v15.i4.150
Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome
Tian-Yu Liang, Li-Hai Lu, Si-Yu Tang, Zi-Hao Zheng, Kai Shi, Jing-Quan Liu
Tian-Yu Liang, Jing-Quan Liu, Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China
Li-Hai Lu, Zi-Hao Zheng, Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Si-Yu Tang, The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Kai Shi, Department of Respiratory Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Author contributions: All the authors had full access to all the data of the article, who were responsible for data integrity and accuracy; Liu JQ and Liang TY drafted the manuscript; Tang SY, Zheng ZH and Shi K designed the tables and figures; Lu LH worked on supervision; All authors approved the final version of the manuscript.
Supported byThe Youth Fund project of the Natural Science Foundation of Zhejiang Province, No. LQ20H15010; and Zhejiang Traditional Chinese Medicine Science and Technology Planning Project, No. 2023ZL575.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing-Quan Liu, MD, Doctor, Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), No. 158 Shangtang Road, Gongshu District, Hangzhou 310014, Zhejiang Province, China. liujqaticu@163.com
Received: December 20, 2022 Peer-review started: December 20, 2022 First decision: January 6, 2023 Revised: January 20, 2023 Accepted: March 20, 2023 Article in press: March 20, 2023 Published online: April 26, 2023 Processing time: 127 Days and 0.1 Hours
Abstract
Acute respiratory distress syndrome (ARDS) is a common and clinically devastating disease that causes respiratory failure. Morbidity and mortality of patients in intensive care units are stubbornly high, and various complications severely affect the quality of life of survivors. The pathophysiology of ARDS includes increased alveolar–capillary membrane permeability, an influx of protein-rich pulmonary edema fluid, and surfactant dysfunction leading to severe hypoxemia. At present, the main treatment for ARDS is mechanical treatment combined with diuretics to reduce pulmonary edema, which primarily improves symptoms, but the prognosis of patients with ARDS is still very poor. Mesenchymal stem cells (MSCs) are stromal cells that possess the capacity to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as the umbilical cord, endometrial polyps, menstrual blood, bone marrow, and adipose tissues. Studies have confirmed the critical healing and immunomodulatory properties of MSCs in the treatment of a variety of diseases. Recently, the potential of stem cells in treating ARDS has been explored via basic research and clinical trials. The efficacy of MSCs has been shown in a variety of in vivo models of ARDS, reducing bacterial pneumonia and ischemia-reperfusion injury while promoting the repair of ventilator-induced lung injury. This article reviews the current basic research findings and clinical applications of MSCs in the treatment of ARDS in order to emphasize the clinical prospects of MSCs.
Core Tip: Acute respiratory disease syndrome (ARDS) is a common disease with high morbidity and mortality. ARDS is characterized by increased alveolar-capillary membrane permeability, influx of protein-rich pulmonary edema fluid, and surfactant dysfunction, resulting in severe hypoxemia. Mesenchymal stem cells (MSCs) have the self-renewal and multilineage differentiation properties, and their immunomodulatory abilities have been implicated in the treatment of disease. Herein, we discuss the pathophysiology of ARDS and recent research surrounding the clinical application of MSCs in the treatment of ARDS.
